Yakult begins ThermoDox trials as pharma sales rise
This article was originally published in Scrip
Executive Summary
Following its acquisition of Japanese rights last year, Yakult Honsha has joined a global Phase III trial programme for Celsion's doxorubicin product ThermoDox in primary liver cancer.
You may also be interested in...
Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Need a specific report? 1000+ reports available
Buy Reports